Biodexa Pharmaceuticals PLC, a public limited company, has filed a Prospectus Supplement No. 2 with the Securities and Exchange Commission (SEC) on May 29, 2024. This filing amends and supplements the company's previous prospectus related to the resale of 1,192,023,200 ordinary shares, represented by 2,980,058 American Depositary Shares (ADSs), by selling shareholders. The Prospectus Supplement incorporates information from the company's Form 6-K filed on May 28, 2024. Biodexa Pharmaceuticals has also announced the closure of a transaction involving the exercise of existing Series E and Series F warrants by certain accredited investors, resulting in the issuance of replacement Series G and Series H warrants. The exercised warrants will lead to the issuance of 4,036,151 ADSs, with each ADS representing 400 ordinary shares. The company received gross proceeds of approximately $6.05 million from the warrant exercises, before deducting fees and estimated offering expenses. Additionally, placement agent warrants were issued to Ladenburg Thalmann & Co., Inc. The company's ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX,' with a reported closing price of $1.08 on May 28, 2024.

Biodexa Pharmaceuticals PLC, a public limited company, has filed a Prospectus Supplement No. 2 with the Securities and Exchange Commission (SEC) on May 29, 2024. This filing amends and supplements the company's previous prospectus related to the resale of 1,192,023,200 ordinary shares, represented by 2,980,058 American Depositary Shares (ADSs), by selling shareholders. The Prospectus Supplement incorporates information from the company's Form 6-K filed on May 28, 2024. Biodexa Pharmaceuticals has also announced the closure of a transaction involving the exercise of existing Series E and Series F warrants by certain accredited investors, resulting in the issuance of replacement Series G and Series H warrants. The exercised warrants will lead to the issuance of 4,036,151 ADSs, with each ADS representing 400 ordinary shares. The company received gross proceeds of approximately $6.05 million from the warrant exercises, before deducting fees and estimated offering expenses. Additionally, placement agent warrants were issued to Ladenburg Thalmann & Co., Inc. The company's ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX,' with a reported closing price of $1.08 on May 28, 2024.